Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Akermin was an industrial biotechnology company that developed biocatalytic solutions for carbon capture and industrial gas processing. The company's core technology was a proprietary Biocatalyst Delivery System (BDS), which utilized the enzyme carbonic anhydrase immobilized within a stable polymer matrix to efficiently remove carbon dioxide from industrial exhaust streams. This approach was designed to be more energy-efficient and environmentally sustainable than conventional chemical solvent-based scrubbing methods. Headquartered in St. Louis, Missouri, Akermin successfully demonstrated its technology in several pilot programs before its assets were acquired by Oxy Low Carbon Ventures in 2019.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Akermin.